OBJECTIVE Knowledge of the molecular and cellular changes that occur during the
transition of hormone‐naïve to castration‐resistant prostate cancer (CRPC) is increasing …

Androgens and the androgen receptor (AR) play crucial roles in the biology of normal and
diseased prostate tissue, including prostate cancer (PCa). This dependence is evidenced by …

Context Androgen deprivation therapy (ADT) is the backbone of treatment for advanced
prostate cancer. However, castration-resistant prostate cancer (CRPC) nearly invariably …

The androgen-signaling axis plays a pivotal role in the pathogenesis of prostate cancer.
Since the landmark discovery by Huggins and Hodges, gonadal depletion of androgens has …

The metabolic functions of androgen receptor (AR) in normal prostate are circumvented in
prostate cancer (PCa) to drive tumor growth, and the AR also can acquire new growth …

Background The emergence of castration resistance has remained the primary obstacle in
prostate cancer therapy for several decades. Mechanisms likely to be involved in castration …

Abstract In the United States, prostate cancer (PCa) is the most commonly diagnosed non-
cutaneous cancer in males and the second leading cause of cancer-related death for men …

The androgen signaling axis in prostate cancer is associated with multiple adaptive
mechanisms in response to castration. Herein we review these adaptations with an …

Systemic treatment of advanced prostate cancer is initiated with androgen deprivation
therapy by gonadal testosterone depletion. Response durations are variable and tumors …

Context Various molecular mechanisms play a role in the development of resistance to
androgen deprivation therapy in castration-resistant prostate cancer (CRPC). Objective To …